181 related articles for article (PubMed ID: 19591486)
1. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
von Guggenberg E; Sallegger W; Helbok A; Ocak M; King R; Mather SJ; Decristoforo C
J Med Chem; 2009 Aug; 52(15):4786-93. PubMed ID: 19591486
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand.
Wang J; Kim YS; Liu S
Bioconjug Chem; 2008 Mar; 19(3):634-42. PubMed ID: 18281926
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
6. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
7. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
[TBL] [Abstract][Full Text] [Related]
8. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
[TBL] [Abstract][Full Text] [Related]
10. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeling approaches for cholecystokinin B receptor imaging.
Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.
von Guggenberg E; Rangger C; Sosabowski J; Laverman P; Reubi JC; Virgolini IJ; Decristoforo C
Mol Imaging Biol; 2012 Jun; 14(3):366-75. PubMed ID: 21732165
[TBL] [Abstract][Full Text] [Related]
13. Trifluoroacetyl-HYNIC peptides: synthesis and 99mTc radiolabeling.
Surfraz MB; King R; Mather SJ; Biagini SC; Blower PJ
J Med Chem; 2007 Mar; 50(6):1418-22. PubMed ID: 17315986
[TBL] [Abstract][Full Text] [Related]
14. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands.
Liu S; Edwards DS; Looby RJ; Harris AR; Poirier MJ; Barrett JA; Heminway SJ; Carroll TR
Bioconjug Chem; 1996; 7(1):63-71. PubMed ID: 8741992
[TBL] [Abstract][Full Text] [Related]
15. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
16. [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation.
Babaei MH; Almqvist Y; Orlova A; Shafii M; Kairemo K; Tolmachev V
Oncol Rep; 2005 Jun; 13(6):1169-75. PubMed ID: 15870939
[TBL] [Abstract][Full Text] [Related]
17. The [Tc(N)(PNP)]2+ metal fragment labeled cholecystokinin-8 (CCK8) peptide for CCK-2 receptors imaging: in vitro and in vivo studies.
Agostini S; Bolzati C; Didonè E; Cavazza-Ceccato M; Refosco F; Aloj L; Arra C; Aurilio M; Tornesello AL; Tesauro D; Morelli G
J Pept Sci; 2007 Apr; 13(4):211-9. PubMed ID: 17269133
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT
J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859
[TBL] [Abstract][Full Text] [Related]
19. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
García-Garayoa E; Maes V; Bläuenstein P; Blanc A; Hohn A; Tourwé D; Schubiger PA
Nucl Med Biol; 2006 May; 33(4):495-503. PubMed ID: 16720241
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
